We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immune Responses Evaluated for Tick-Borne Encephalitis

By LabMedica International staff writers
Posted on 13 May 2020
Print article
Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).
Image: The Simultest IMK-Lymphocyte is a two-color direct immunofluorescence reagent kit for enumerating percentages of the following mature human leucocyte subsets in erythrocyte-lysed whole blood (Photo courtesy of BDBiosciences).
Tick-borne encephalitis (TBE) is an important vector-borne infection of the central nervous system (CNS). The majority of all reported cases of TBE occur in adults. However, TBE should also be included in the differential diagnosis of pediatric CNS infections in endemic areas.

The chemokine CXCL13 is one of the key determinants of the humoral immune response at the site of an infection. CXCL13 is expressed in lymphoid organs and controls the recruitment and compartmentalization of B-cells and CD4+ T lymphocytes within these structures. CXCL13 is produced by microglia, stromal cells in the meninges, and infiltrating lymphoid cells.

Infectious disease specialists at the Medical University of Bialystok (Bialystok, Poland) analyzed anti-tick-borne encephalitis virus (TBEV) antibody levels, cerebrospinal fluid (CSF) and blood lymphoid populations, and concentrations of CXCL13 (a potent B-cell and T-cell chemoattractant), in 35 patients with TBE (20 adults and 15 children). TBE was defined as a febrile illness with signs of meningitis or meningoencephalitis, a CSF cell count of more than 5 cells/μL, and the presence of serum IgM and IgG antibodies to TBEV.

The detection of anti-TBEV IgG and IgM antibodies in serum and CSF was performed by enzyme-linked immunosorbent assay (ELISA), using SERION ELISA classic kits (Würzburg, Germany). The CXCL13 concentration quotient was calculated as QCXCL13 = CXCL13CSF/CXCL13serum. QCXCL13 was used as a measure of the chemical gradient of that chemokine. A value greater than 1 indicates a higher concentration of CXCL13 in the CSF than in the serum. All serum and CSF samples were stored at −80 °C until analysis of the chemokine. For flow cytometry, samples were analyzed within 18 hours on a FACSCanto II cytometer (BDBiosciences, San Jose, CA, USA). The Simultest IMK-Lymphocyte kit from BD Biosciences was used to study peripheral blood and CSF lymphocyte fractions

The scientists reported that when compared with the blood, the CSF lymphoid population was significantly enriched in CD4+ T-cells and relatively depleted in natural killer (NK) cells and B lymphocytes. In comparison with TBE meningitis, patients suffering from TBE meningoencephalitis (11, 31%) had a 3.5-fold higher median CSF CXCL13 concentration, 1.8-fold higher CSF/serum ratio of anti-TBEV IgG antibodies, and 1.8-fold higher median CSF cell count. CSF CXCL13 levels did not change significantly in children with TBE meningitis receiving supportive treatment, but decreased in children with TBE meningoencephalitis who received intravenous steroids.

The authors concluded that the CSF in patients with TBE was abundant in CD4+ cells and relatively depleted in NK cells and in B lymphocytes, when compared with the blood. A higher absolute number of lymphocytes in the CSF were associated with a more severe course of TBE. CXCL13 may be involved in the neuropathology of TBE by attracting different subsets of lymphocytes into the CSF, but it remains unclear whether this chemokine contributes directly to disease severity. The study was published on April 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Medical University of Bialystok
SERION
BDBiosciences


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.